U.S. Ads to Challenge Value of E-Cigarettes
Download the Wall Street Journal app here: WSJ.
U.S. Ads to Challenge Value of E-Cigarettes
Download the Wall Street Journal app here: WSJ.
The Center on Alcoholism, Substance Abuse, and Addictions (CASAA) announces two new postdoctoral positions on our NIAAA Institutional Research Training grant. The goal of the grant is to prepare future NIH scientists to conduct research to (1) elucidate the processes of change in drinking behavior, (2) develop and test effective methods to effect change through self-change, treatment and indicated prevention, and (3) develop and test models to disseminate knowledge of effective interventions to diverse populations. Postdoctoral fellows work with one of the core training faculty: Barbara S. McCrady (PI and training program director), Eric Claus, Jon Houck, Theresa Moyers, Matthew Pearson, J. Scott Tonigan, Kamilla Venner, Katie Witkiewitz, or W. Gill Woodall.
In anticipation of renewal funding, we have three openings to support postdoctoral fellows in the 2015-2016 academic year. Applicants must meet the following criteria: (1) demonstrated interest in the alcohol field as evidenced by prior coursework, research, and/or clinical experience; (2) a record of research productivity as evidenced by research presentations and peer-reviewed publications; and (3) a commitment to a career in alcohol research. All fellows must be US citizens or permanent resident aliens.
As part of the training program, fellows must be engaged in full-time research training, participate in a weekly Addictions seminar, define a training plan and achieve specific competencies during each year, and limit outside employment. For continued support post-doctoral fellows will be expected to prepare and successfully submit an NIH grant application.
The training program provides a NIH-defined stipend (based on years since doctoral degree), tuition remission, support for professional travel up to $2000 per year, and support for training- and research-related expenses.
Interested applicants should submit a curriculum vitae, 3 letters of recommendation, 1-page statement of interest, letter stating their qualifications for and interest in the training grant, and their graduate transcripts to Barbara McCrady. Applications will reviewed on a rolling basis. Submit all materials electronically to:
Barbara S. McCrady, Ph.D.
Distinguished Professor of Psychology
Director, Center on Alcoholism, Substance Abuse, and Addictions (CASAA)
University of New Mexico
2650 Yale Blvd. SE
Albuquerque, NM 87106
See http://casaa.unm.edu/traininggrant.html for information about the training program
Response requested April 10, 2015.
The National Institute on Drug Abuse published RFI NOT-DA-15-052 seeking information about the availability of data from biological specimens (such as blood, plasma, isolated cells [PBMCs]) obtained from HIV Infected and non-infected injection drug using (IDU) subjects. This information will be used to determine the feasibility of developing programs for conducting genetic and epigenetic analyses of data on the host-response to HIV and modalities of personalized (precision) medicine for treating HIV infection in IDUs.
Drug addiction is a major factor in driving the AIDS and hepatitis C epidemics. Globally, an estimated 16 million people inject drugs and 3 million of them are living with HIV. On average one out of every ten new HIV infections is caused by injection drug use; in parts of Eastern Europe and Central Asia, over 80% of all HIV infections is related to drug use (WHO; http://www.who.int/hiv/topics/idu/en/). Further, up to 90% of HIV infected IDUs may also be infected with hepatitis C.
While a large number of clinical samples have been collected from HIV-infected and non-infected drug abusing patients/subjects over the past 30 years, the number and type of basic and clinical information from biological specimens (blood, plasma, isolated cells such as PBMCs etc.) is not known. The earlier successes of the 1200 genome wide association studies (GWAS identifying variants for more than 200 diseases and traits, is frequently dependent on the development of consortia to generate sufficient power to detect gene variants. Thus, knowledge about the number and type of available data and bio-specimens is needed to make informed decision about the feasibility of developing programs for conducting genetic and epigenetic analysis of injecting drug use, the host-response to HIV, and models of (personalized) precision medicine for treating HIV infection and injection drug use.
If you have clinical data and bio-specimens from HIV- and Non-infected HIV Injection Drug Users, we request that you provide information about the clinical data and bio-specimens. We request that you provide this information to us by April 10, 2015. Your comments can include but are not limited to the following examples of the type of information that would be helpful : 1) The principle Investigator and Assistant contact information; 2) patient information: (i) type and number of bio-specimens collected; (ii) HIV and HCV status (iii) viral load, CD4 count, (iv) clinical assessment including standard blood work-up for metabolic and hepatic panels; and finally (v) treatment status: antiretroviral regimen used .
Clinical data about substance abuse might include: i) onset (early versus late) of drug use, the amount, frequency, pattern (binge or escalated use), type of drug used, route of drug administration, and amount of money spent; (ii) biomarker used to quantity the drug use; iii) DSMIII-R and DSMIV symptoms; iv) measures of withdrawal severity such as the Clinical Opiate Withdrawal Scale (COWS) or other measures of withdrawal for other substances; v) time spent seeking a drug; vi) duration of abstinence; vii) number of quit attempts; viii) other co-morbid psychiatric disorders; ix) environmental variables; x) instruments used to assess substance use; and xi) the method of sample collection.
Other information that would be helpful is whether the research participants are consented for genetic studies or can be re-contacted to obtain consent, and whether a whole genome association scan has been performed on the research participant. If a genome wide scan has been performed, please provide the platform used and the where the genotypic and phenotypic data can be located.
Submitting a Response
All responses must be submitted via email to NIDAInjectionDrugUse@mail.nih.gov by April 10, 2015. Please include the Notice number in the subject line. Response to this RFI is voluntary. Responders are free to address any or all of the categories listed above. The submitted information will be reviewed by the NIH staff.
This request is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government. The NIH does not intend to make any awards based on responses to this RFI or to otherwise pay for the preparation of any information submitted or for the Government's use of such information.
The NIH will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder's submission. However, responses to the RFI may be reflected in future funding opportunity announcements. The information provided will be analyzed and may be aggregated in reports. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to firstname.lastname@example.org<mailto:email@example.com. Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact Jonathan D. Pollock, Ph.D. firstname.lastname@example.org 301-435-1309
- The conference will kick-off in the Hotel Monaco Baltimore at 12:45pm on Friday March 6th in the Paris Ballroom (3rd Floor). http://research.alcoholstudies.rutgers.edu/cpa/schedule
- The registration desk will be in the Paris foyer (3rd Floor, outside of the Paris Ballroom) and will be open from 7am-5pm Friday and Saturday.
- Sign-up information for receiving continuing education credits at the meeting (up to 12.25 CE credits) will be available at the registration desk.
- There is a $20 CE processing fee, which can be paid using cash, check or credit card.
- Posters: The poster board format for the conference is horizontal (i.e., landscape) and the poster boards will be 4 feet tall by 6 feet wide (48” by 72”).
- Symposia: Please bring a laptop with talks pre-loaded or a USB drive. Projectors, screens, and microphones will be provided. We will have AV support available to help.
Sign-up for the FREE Kimpton Karma Rewards guest loyalty program for special offers (including free internet) during your stay: https://www.kimptonhotels.com/karma-rewards/overview
Fitness Center: 24 hour access (located on the 3rd Floor)
(FREE) Wine Hour: Living Room, daily 5pm-6pm
(FREE) Coffee: Living Room, weekdays 6am-9am, weekends 7am-10am
Charm City Circulator: FREE transportation around the city (www.charmcitycirculator.com)
Baltimore Metro: Charles Street stop (directly across from hotel)
Light Rail: University Center-Baltimore Street stop (2 blocks away)
Downtown Parking Information: http://baltimore.bestparking.com/
We look forward to seeing everyone in Baltimore!